| Overview |
| bs-21419R-Cy5.5 |
| Klrb1 Polyclonal Antibody, Cy5.5 Conjugated |
| WB |
| Human |
| Mouse, Rat |
| Specifications |
| Cy5.5 |
| Rabbit |
| KLH conjugated synthetic peptide derived from rat Klrb1 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 362443 |
| Q0ZUP0 |
| Cell membrane |
| Killer cell lectin-like receptor subfamily B member 1; Killer cell lectin-like receptor subfamily B member 1G; Natural killer cell surface protein NKR-P1G; Natural killer lectin-like receptor 1E; Gm4696; Klrb1d; Klrb1g; Klrb6; Nkrp1g; Ly55; Ly-55; NKR-P1G; Nkrp-1e; 4930431A04Rik; KLRB1_MOUSE; KLRB1_RAT; CD161c(mouse); CD161a(rat); |
| Plays an inhibitory role on natural killer (NK) cells cytotoxicity. Activation results in specific acid sphingomyelinase/SMPD1 stimulation with subsequent marked elevation of intracellular ceramide. Activation also leads to AKT1/PKB and RPS6KA1/RSK1 kinases stimulation as well as markedly enhanced T-cell proliferation induced by anti-CD3. Acts as a lectin that binds to the terminal carbohydrate Gal-alpha(1,3)Gal epitope as well as to the N-acetyllactosamine epitope. Binds also to CLEC2D/LLT1 as a ligand and inhibits NK cell-mediated cytotoxicity as well as interferon-gamma secretion in target cells. |
| Application Dilution |
| WB |
1:300-5000 |
Powered by Bioz